OTCPK:MDIT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Medite Cancer Diagnostics

Executive Summary

Medite Cancer Diagnostics, Inc. operates as a medical technology company. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Medite Cancer Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDIT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-48.3%

MDIT

0.6%

US Medical Equipment

0.09%

US Market


1 Year Return

-95.5%

MDIT

14.8%

US Medical Equipment

12.6%

US Market

Return vs Industry: MDIT underperformed the US Medical Equipment industry which returned 14.8% over the past year.

Return vs Market: MDIT underperformed the US Market which returned 12.6% over the past year.


Shareholder returns

MDITIndustryMarket
7 Day-48.3%0.6%0.09%
30 Day-88.5%0.9%-1.6%
90 Day-93.5%11.4%7.9%
1 Year-95.5%-95.5%15.8%14.8%15.2%12.6%
3 Year-99.2%-99.2%72.3%67.9%38.9%29.6%
5 Year-99.7%-99.7%148.2%129.3%87.6%66.5%

Price Volatility Vs. Market

How volatile is Medite Cancer Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medite Cancer Diagnostics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Medite Cancer Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Medite Cancer Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Medite Cancer Diagnostics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Medite Cancer Diagnostics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Medite Cancer Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medite Cancer Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Medite Cancer Diagnostics performed over the past 5 years?

15.4%

Historical Healthcare annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if MDIT has high quality earnings.

Growing Profit Margin: Insufficient data to determine if MDIT's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if MDIT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare MDIT's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if MDIT's earnings growth over the past year exceeded the Medical Equipment industry average.


Return on Equity

High ROE: MDIT has a negative Return on Equity (0%), as it is currently unprofitable.


Next Steps

Financial Health

How is Medite Cancer Diagnostics's financial position?


In this section we usually analyse Medite Cancer Diagnostics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Medite Cancer Diagnostics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of MDIT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Medite Cancer Diagnostics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Medite Cancer Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDIT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDIT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDIT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average board tenure


CEO

Medite Cancer Diagnostics has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
John Abeles
Independent Director21.33yrsUS$123.88k0.14%
$ 360.7
Joel Kanter
Independent Director2.83yrsno data0.39%
$ 1.0k
Gregory Fortunoff
Director2.67yrsno data1.89%
$ 5.0k
William Lewis
Independent Chairman of Boardno dataUS$168.66k0%
$ 0

2.8yrs

Average Tenure

56.5yo

Average Age

Experienced Board: MDIT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medite Cancer Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medite Cancer Diagnostics, Inc.
  • Ticker: MDIT
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$266.008k
  • Shares outstanding: 85.81m
  • Website: https://medite-group.com

Number of Employees


Location

  • Medite Cancer Diagnostics, Inc.
  • 10524 Moss Park Road
  • Suite 204-357
  • Orlando
  • Florida
  • 32832
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDITOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 1998

Biography

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 05:50
End of Day Share Price2020/09/15 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.